Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
DAIICHI SANKYO UNSP/ADR (DSKYY.PK)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: DSKYY.PK
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
52wk high:
52wk low:
EPS:
PE:
Dividend:
Yield:
Market Cap:
Exchange:
Analysis - Latest Articles
Brilinta Data Should Soothe Some of AstraZeneca's Patent Cliff Woes
EP Vantage
•
Sep 02
•
Comment!
Lilly and Daiichi Finally Receive Effient Approval
EP Vantage
•
Jul 15
•
Comment!
Generic Players Continue to Impress in H1
EP Vantage
•
Jul 02
•
Comment!
FDA Decisions and Clinical Trials: An Updated Calendar
Mike Havrilla
•
Feb 06
•
2 Comments
Two FDA New Product Decisions Expected This Week for Eli Lilly, Dyax
Mike Havrilla
•
Feb 03
•
Comment!
Trading the Trials and FDA Decision Calendar
Mike Havrilla
•
Jan 26
•
1 Comment
More articles on DSKYY.PK »
Instablogs
Generic players continue to impress in the first half
Thu July 2, 2009
•
EP Vantage
•
Comment!
Write a post on DSKYY.PK
|
More Instablogs on DSKYY.PK »
Sentiment
What advice would you give to
DSKYY.PK?
119 characters left
What's your view of DSKYY.PK?
Make sure you include DSKYY.PK
140 characters left
|
Settings